Beneficial synergistic interactions of TNF-α and IL-6 in C2 skeletal myoblasts - Potential cross-talk with IGF system

Growth Factors

Volumn 26, Issue 2, 2008, Pages 61-73

  Al Shanti, Nasser ^a   Saini, Amarjit ^a   Faulkner, Steve H ^a   Stewart, Claire E ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Differentiation; IL 6; Proliferation; Signal transducer gp130; Survival; TNF

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RECEPTOR GP130; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE; MYOBLASTS, SKELETAL; RECEPTORS, SOMATOMEDIN; SOMATOMEDINS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 42549159606     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190802025024     Document Type: Article

References (62)

1. Akira, S., Taga, T. and Kishimoto, T. (1993) Interleukin-6 in biology and medicine. Adv Immunol, 54, pp. 1-78.
2. Alvarez, B., Quinn, LS, Busquets, S., Lopez-Soriano, FJ and Argiles, JM (2002) TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett, 175, pp. 181-185.
3. Alvarez, B., Quinn, LS, Busquets, S., Quiles, MT, Lopez-Soriano, FJ and Argiles, JM (2002) Tumor necrosis factor-alpha exerts interleukin-6-dependent and - independent effects on cultured skeletal muscle cells. Biochim Biophys Acta, 1542, pp. 66-72.
4. Argiles, JM and Lopez-Soriano, FJ (1998) Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care, 1, pp. 245-251.
5. Argiles, JM, Busquets, S., Felipe, A. and Lopez-Soriano, FJ (2006) Muscle wasting in cancer and ageing: Cachexia versus sarcopenia. Adv Gerontol, 18, pp. 39-54.
6. Bartoccioni, E., Michaelis, D. and Hohlfeld, R. (1994) Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett, 42, pp. 135-138.
7. Barton, BE (2001) IL-6-like cytokines and cancer cachexia: Consequences of chronic inflammation. Immunol Res, 23, pp. 41-58.
8. Barton, BE and Murphy, TF (2000) Constitutive expression of IL-6-like cytokines in normal bone marrow: Implications for pathophysiology of myeloma. Cytokine, 12, pp. 1537-1545.
9. Brown, AL, Graham, DE, Nissley, SP, Hill, DJ, Strain, AJ and Rechler, MM (1986) Developmental regulation of insulin-like growth factor II mRNA in different rat tissues. J Biol Chem, 261, pp. 13144-13150.
10. Cahlin, C., Korner, A., Axelsson, H., Wang, W., Lundholm, K. and Svanberg, E. (2000) Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res, 60, pp. 5488-5493.
11. Cantini, M., Massimino, ML, Rapizzi, E., Rossini, K., Catani, C., Libera, L Dalla and Carraro, U. (1995) Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. Biochem Biophys Res Commun, 216, pp. 49-53.
12. Coolican, SA, Samuel, DS, Ewton, DZ, McWade, FJ and Florini, JR (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem, 272, pp. 6653-6662.
13. De Benedetti, F., Alonzi, T., Moretta, A., Lazzaro, D., Costa, P., Poli, V., Martini, A., Ciliberto, G. and Fattori, E. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest, 99, pp. 643-650.
14. De Rossi, M., Bernasconi, P., Baggi, F., Malefyt, R de Waal and Mantegazza, R. (2000) Cytokines and chemokines are both expressed by human myoblasts: Possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol, 12, pp. 1329-1335.
15. Fang, CH, Sun, X., Li, BG, Fischer, DR, Pritts, TA, Penner, G. and Hasselgren, PO (2000) Burn injuries in rats upregulate the gene expression of the ubiquitin-conjugating enzyme E2(14k) in skeletal muscle. J Burn Care Rehabil, 21, pp. 528-534.
16. Febbraio, MA (2003) Signaling pathways for IL-6 within skeletal muscle. Exerc Immunol Rev, 9, pp. 34-39.
17. Febbraio, MA and Pedersen, BK (2002) Muscle-derived interleukin-6: Mechanisms for activation and possible biological roles. FASEB J, 16, pp. 1335-1347.
18. Fiers, W. (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett, 285, pp. 199-212.
19. Florini, JR, Magri, KA, Ewton, DZ, James, PL, Grindstaff, K. and Rotwein, PS (1991) "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J Biol Chem, 266, pp. 15917-15923.
20. Foulstone, EJ, Meadows, KA, Holly, JM and Stewart, CE (2001) Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. J Cell Physiol, 189, pp. 207-215.
21. Foulstone, EJ, Huser, C., Crown, AL, Holly, JM and Stewart, CE (2004) Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: Roles of IGF-I and TNFalpha. Exp Cell Res, 294, pp. 223-235.
22. Gallucci, S., Provenzano, C., Mazzarelli, P., Scuderi, F. and Bartoccioni, E. (1998) Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol, 10, pp. 267-273.
23. Godar, S., Horejsi, V., Weidle, UH, Binder, BR, Hansmann, C. and Stockinger, H. (1999) M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol, 29, pp. 1004-1013.
24. Grimble, RF (2003) Inflammatory response in the elderly. Curr Opin Clin Nutr Metab Care, 6, pp. 21-29.
25. Guttridge, DC, Mayo, MW, Madrid, LV, Wang, CY and Baldwin Jr, AS (2000) NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science, 289, pp. 2363-2366.
26. Hasselgren, PO, Menconi, MJ, Fareed, MU, Yang, H., Wei, W. and Evenson, A. (2005) Novel aspects on the regulation of muscle wasting in sepsis. Int J Biochem Cell Biol, 37, pp. 2156-2168.
27. Hill, DJ, Crace, CJ, Nissley, SP, Morrell, D., Holder, AT and Milner, RD (1985) Fetal rat myoblasts release both rat somatomedin-C (SM-C)/ insulin-like growth factor I (IGF I) and multiplication-stimulating activity in vitro: Partial characterization and biological activity of myoblast-derived SM-C/IGF I. Endocrinology, 117, pp. 2061-2072.
28. Hirano, T., Ishihara, K. and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 19, pp. 2548-2556.
29. James, PL, Stewart, CE and Rotwein, P. (1996) Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism. J Cell Biol, 133, pp. 683-693.
30. Jourdan, M., Zhang, XG, Portier, M., Boiron, JM, Bataille, R. and Klein, B. (1991) IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol, 147, pp. 4402-4407.
31. Kallen, KJ (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta, 1592, pp. 323-343.
32. Langen, RC, Schols, AM, Kelders, MC, van Der Velden, JL, Wouters, EF and Janssen-Heininger, YM (2002) Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol, 283, pp. C714-C721.
33. Langen, RC, van Der Velden, JL, Schols, AM, Kelders, MC, Wouters, EF and Janssen-Heininger, YM (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J, 18, pp. 227-237.
34. Lawlor, MA, Feng, X., Everding, DR, Sieger, K., Stewart, CE and Rotwein, P. (2000) Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways. Mol Cell Biol, 20, pp. 3256-3265.
35. Layne, MD and Farmer, SR (1999) Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp Cell Res, 249, pp. 177-187.
36. Li, YP and Reid, MB (2000) NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol, 279, pp. R1165-R1170.
37. Li, YP, Schwartz, RJ, Waddell, ID, Holloway, BR and Reid, MB (1998) Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J, 12, pp. 871-880.
38. Lloyd-Williams, F., Mair, FS and Leitner, M. (2002) Exercise training and heart failure: A systematic review of current evidence. Br J Gen Pract, 52, pp. 47-55.
39. Matthys, P., Mitera, T., Heremans, H., van Damme, J. and Billiau, A. (1995) Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in d-galactosamine-sensitized and unsensitized mice. Infect Immun, 63, pp. 1158-1164.
40. Meadows, KA, Holly, JM and Stewart, CE (2000) Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol, 183, pp. 330-337.
41. Mizuhara, H., O'Neill, E., Seki, N., Ogawa, T., Kusunoki, C., Otsuka, K., Satoh, S., Niwa, M., Senoh, H. and Fujiwara, H. (1994) T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med, 179, pp. 1529-1537.
42. Molotkov, A., Satoh, M. and Tohyama, C. (1998) Tumor growth and food intake in interleukin-6 gene knock-out mice. Cancer Lett, 132, pp. 187-192.
43. Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T. and Kishimoto, T. (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science, 260, pp. 1808-1810.
44. Ogata, A., Chauhan, D., Urashima, M., Teoh, G., Treon, SP and Anderson, KC (1997) Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res, 3, pp. 1017-1022.
45. Pedersen, BK, Steensberg, A., Fischer, C., Keller, C., Keller, P., Plomgaard, P., Febbraio, M. and Saltin, B. (2003) Searching for the exercise factor: Is IL-6 a candidate?. J Muscle Res Cell Motil, 24, pp. 113-119.
46. Pedersen, BK, Steensberg, A., Keller, P., Keller, C., Fischer, C., Hiscock, N., van Hall, G., Plomgaard, P. and Febbraio, MA (2003) Muscle-derived interleukin-6: Lipolytic, anti-inflammatory and immune regulatory effects. Pflugers Arch, 446, pp. 9-16.
47. Radonic, A., Thulke, S., Mackay, IM, Landt, O., Siegert, W. and Nitsche, A. (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun, 313, pp. 856-862.
48. Rose-John, S., Waetzig, GH, Scheller, J., Grotzinger, J. and Seegert, D. (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets, 11, pp. 613-624.
49. Schmid, C., Steiner, T. and Froesch, ER (1983) Preferential enhancement of myoblast differentiation by insulin-like growth factors (IGF I and IGF II) in primary cultures of chicken embryonic cells. FEBS Lett, 161, pp. 117-121.
50. Steensberg, A., Febbraio, MA, Osada, T., Schjerling, P., van Hall, G., Saltin, B. and Pedersen, BK (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol, 537, pp. 633-639.
51. Steensberg, A., Keller, C., Starkie, RL, Osada, T., Febbraio, MA and Pedersen, BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab, 283, pp. E1272-E1278.
52. Steensberg, A., Keller, C., Starkie, RL, Osada, T., Febbraio, MA and Pedersen, BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab, 283, pp. E1272-E1278.
53. Stewart, CE and Rotwein, P. (1996) Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev, 76, pp. 1005-1026.
54. Stewart, KJ, Hiatt, WR, Regensteiner, JG and Hirsch, AT (2002) Exercise training for claudication. N Engl J Med, 347, pp. 1941-1951.
55. Suman, OE, Spies, RJ, Celis, MM, Mlcak, RP and Herndon, DN (2001) Effects of a 12-wk resistance exercise program on skeletal muscle strength in children with burn injuries. J Appl Physiol, 91, pp. 1168-1175.
56. Thaloor, D., Miller, KJ, Gephart, J., Mitchell, PO and Pavlath, GK (1999) Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol, 277, pp. C320-C329.
57. Tuzun, E., Li, J., Wanasen, N., Soong, L. and Christadoss, P. (2006) Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. Cytokine, 35, pp. 100-106.
58. Vermes, C., Jacobs, JJ, Zhang, J., Firneisz, G., Roebuck, KA and Glant, TT (2002) Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts. J Biol Chem, 277, pp. 16879-16887.
59. Wang, H., Casaburi, R., Taylor, WE, Aboellail, H., Storer, TW and Kopple, JD (2005) Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients. Kidney Int, 68, pp. 352-361.
60. Wang, W., Slevin, M., Kumar, S. and Kumar, P. (2005) The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol, 27, pp. 1087-1096.
61. Weyman, CM and Wolfman, A. (1998) Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology, 139, pp. 1794-1800.
62. Yaffe, D. and Saxel, O. (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, 270, pp. 725-727.